ADMA Biologics (ADMA) vs Adaptive Biotechnologies (ADPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed ADMA Biologics (ADMA) over the past year, gaining 50.1% versus a loss of 23.3%. Over five years, ADMA leads with a +808.3% price change compared with -0.7% for ADPT. Adaptive Biotechnologies is the larger company by market cap ($4.52 billion vs $2.92 billion), about 1.5 times the size.
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -21.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | ADPT |
|---|---|---|
| Share price | $13.17 | $27.93 |
| Market cap | $2.92B | $4.52B |
| 1-day change | -1.27% | -0.43% |
| YTD return | -27.80% | +71.98% |
| 1-year return | -23.34% | +50.08% |
| 5-year return | +808.28% | -0.68% |
| P/E ratio (TTM) | 17.10 | — |
| Forward P/E | 14.06 | — |
| EPS (TTM) | $0.77 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $276.98M |
| Revenue growth (YoY) | +19.63% | +54.77% |
| Net income (latest FY) | $146.93M | $-59.50M |
| Gross margin | 57.39% | 74.24% |
| Operating margin | 37.53% | -20.62% |
| Net margin | 28.80% | -21.48% |
| 52-week high | $20.46 | $32.21 |
| 52-week low | $7.21 | $12.00 |
| Distance from 52-week high | -35.62% | -13.29% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +36.67% | +21.23% |
| Average volume | 3.23M | 2.20M |
| Shares outstanding | 221.85M | 161.88M |
| Employees | 640 | 624 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed ADMA by 73.4 percentage points over the past year.
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -21.5 cents for Adaptive Biotechnologies.
- Adaptive Biotechnologies grew revenue faster in its latest fiscal year (+54.77% vs +19.63%).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
ADMA vs ADPT FAQ
Which is bigger, ADMA Biologics or Adaptive Biotechnologies?
Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.52B compared with $2.92B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or ADPT?
ADPT returned +50.08% over the past 12 months, compared with -23.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Adaptive Biotechnologies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.